SynAct Pharma AB (SYNACT) — Cash Flow-to-Debt Ratio
SynAct Pharma AB (SYNACT) has a Cash Flow-to-Debt Ratio of -0.75x as of March 2026, meaning its operating cash flow of Skr-32.95 Million could theoretically repay -1% of its total liabilities (Skr44.13 Million) in one year. Check SynAct Pharma AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SynAct Pharma AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for SynAct Pharma AB across 10 annual periods. Also explore SynAct Pharma AB balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for SynAct Pharma AB (2016–2025)
Year-by-year debt coverage analysis for SynAct Pharma AB. For market capitalisation and broader financial context, see SynAct Pharma AB market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.94x | Skr-97.33 Million | Skr50.23 Million | ▼ -22.4% |
| 2024 | -1.58x | Skr-89.20 Million | Skr56.35 Million | ▲ +18.1% |
| 2023 | -1.93x | Skr-100.18 Million | Skr51.83 Million | ▲ +73.6% |
| 2022 | -7.31x | Skr-117.56 Million | Skr16.08 Million | ▼ -96.9% |
| 2021 | -3.71x | Skr-65.00 Million | Skr17.50 Million | ▲ +36.0% |
| 2020 | -5.81x | Skr-33.24 Million | Skr5.72 Million | ▼ -271.3% |
| 2019 | -1.56x | Skr-16.12 Million | Skr10.31 Million | ▲ +76.0% |
| 2018 | -6.52x | Skr-24.21 Million | Skr3.72 Million | ▲ +12.4% |
| 2017 | -7.44x | Skr-17.20 Million | Skr2.31 Million | ▼ -76.3% |
| 2016 | -4.22x | Skr-14.73 Million | Skr3.49 Million | — |